Report: VA, DoD EHR Contracts to Spur Federal Health IT Spending

April 16, 2018
The federal government has estimated that federal healthcare spending will increase 80 percent, from $918 billion in 2015 to $1.7 trillion in 2025, with one of the key IT-related factors being the VA's and DoD's implementations of new EHR systems.

The federal government has estimated that federal healthcare spending will increase 80 percent, from $918 billion in 2015 to $1.7 trillion in 2025, with one of the key IT-related factors being the Department of Veterans Affairs’ (VA) and Department of Defense’s (DoD) implementations of new EHR (electronic health record) systems.

The estimation, coming from Deltek’s Federal Health Information Technology Market report, noted that “Federal health IT spending over the forecasted period is greatly influenced by these new EHR platforms as well as potential solutions by the Coast Guard and Department of State. Efforts to increase medical innovation, mobile health, healthcare cost control and combat public health issues such as the current opioid epidemic will also solidify investments in health IT products and services.”

The report’s authors also stated that requirements for improved quality, interoperability, data sharing and privacy will drive federal agencies taking on the role of promoter, provider or payer to invest in more IT solutions for enhanced health effects and to thwart waste, fraud and abuse.

Deltek also forecasted that spending on vendor-provided federal health IT goods and services will increase from $6.1 billion in 2018 to $8.1 billion in 2023, at a compound annual growth rate (CAGR) of 5.6 percent.

Both the DoD and VA have awarded their EHR modernization contracts to the Kansas City-based health IT vendor Cerner, among other companies involved in the project. Reports have surfaced that the VA-Cerner contract, which has not yet been signed, will be in the $10 billion range, making it one of the largest health IT implementations in history. The hefty cost has concerned Congressional members since that $10 billion figure doesn’t even include infrastructure improvements or implementation support.

Meanwhile, the DoD has begun to implement the Cerner system across a few of its sites, but recently it was announced that they will be suspending the rollout for a few months so that the successes and failures of implementations that have been deployed can be reviewed. The Coast Guard also just recently stated their intentions to join the DoD in transitioning its service members’ and clinics’ health records to the DoD’s MHS Genesis EHR system. The Department of Defense has a 10-year, $4.3 billion contract to build and rollout the Cerner EHR.

Other findings from the report included:

  • A growing Medicare population and increased military and veteran health costs will cause federal healthcare expenditures to continue to rise, forcing agencies to prioritize costs in areas of efficiency and improved outcomes.
  • Federal agencies are using COTS, shared services, cloud and cyber solutions for health IT infrastructure and legacy system upgrades.
  • Legislation and policies such as the HITECH Act, MACRA, the 21st Century Cures Act and MyHealthEData will continue to pave the way for health IT on a nationwide level. However, budget cuts in related federal health agencies will temper their spending on health IT solutions.
  • A growing demand in mobile health solutions such as telehealth and telemedicine will drive growth in mobile healthcare products and applications.

Sponsored Recommendations

Ask the Expert: Is Your Patients' Understanding Putting You at Risk?

Effective health literacy in healthcare is essential for ensuring informed consent, reducing medical malpractice risks, and enhancing patient-provider communication. Unfortunately...

Beyond the Silos: Transforming Coordinated Care Across Healthcare Systems

Coordinated healthcare is vital to delivering a high-quality patient experience, yet it has been difficult to systematize across all healthcare settings. Although it has largely...

The Healthcare Provider's Guide to Accelerating Clinician Onboarding

Improve clinician satisfaction and productivity to enhance patient care

ASK THE EXPERT: ServiceNow’s Erin Smithouser on what C-suite healthcare executives need to know about artificial intelligence

Generative artificial intelligence, also known as GenAI, learns from vast amounts of existing data and large language models to help healthcare organizations improve hospital ...

According to an Oct. 10 press release, a report by the World Health Organization (WHO) finds that vaccines against 24 pathogens could reduce the number of antibiotics needed by 22% or 2.5 billion defined daily doses globally every year, supporting worldwide efforts to address antimicrobial resistance (AMR). While some of these vaccines are already available but underused, others would need to be developed and brought to the market as soon as possible. AMR occurs when bacteria, viruses, fungi, and parasites no longer respond to antimicrobial medicines, making people sicker and increasing the risk of illness, death and the spread of infections that are difficult to treat. AMR is driven largely by the misuse and overuse of antimicrobials, yet, at the same time, many people around the world do not have access to essential antimicrobials. Each year, nearly 5 million deaths are associated with AMR globally. Vaccines are an essential part of the response to reduce AMR as they prevent infections, reduce the use and overuse of antimicrobials, and slow the emergence and spread of drug-resistant pathogens. The new report expands on a WHO study published in BMJ Global Health last year. It estimates that vaccines already in use against pneumococcus pneumonia, Haemophilus influenzae type B (Hib, a bacteria causing pneumonia and meningitis) and typhoid could avert up to 106 000 of the deaths associated with AMR each year. An additional 543 000 deaths associated with AMR could be averted annually when new vaccines for tuberculosis (TB) and Klebsiella pneumoniae, are developed and rolled out globally. While new TB vaccines are in clinical trials, one against Klebsiella pneumoniae is in early stage of development.
dreamstime_xxl_210174616_1